Authors : Shawkat Ali1*, Muhammad Asim2, Rubina3, Naveed Yaqoob4, Muheebur Rehman*5, Saifullah khan*6, Saima7, Adam khan Gohar8, Junaid Farooq
Volume : 26
Issue : 1
Year : 2024
Page No : 14
ABSTRACT— The liver infections are the major cause of increasing mortality rate throughout the world.Liver cirrhosis and hepatocellular carcinoma (HCC) cause an estimated 783,000 and 619,000 deaths per yearrespectively. Thyroid dysfunction (TD) represents an extra hepatic manifestation of chronic hepatitis C(CHC). Moreover, the currently approved treatment of CHC is often associated with TD. However, it remainsdebatable if TD is mainly virus or treatment related. The aim of this study was to assess the incidence of TDand to identify its predictors in treated and untreated CHC‑infected patients. Aim of current work was toexplore the effect of interferon therapy on the thyroid profile of viral hepatic patients. A total of 150(are thosepatients who received therapy and 50 is the control group which is given below) HBV and HCV patients whowere receiving peg interferon therapy were assessed for the thyroid profile against 50 patients of untreatedviral hepatic control group. Add methodology. Thyroid profile was relatively higher in younger patients (20-30 years) as compared to control group. A higher level of thyroid hormone was observed in age group of 20to 30 (30.71%) among the exploratory and control group. Female patients show slight elevation in thyroidprofile in contrast to male patients. The observed value of certain thyroid hormones was hyperthyroidism isabout 28% in HCV patients, followed by hypothyroidism 24% and similarly euthyroidism developed in 48%of patients while in HBV patients the hyperthyroidism was noted 35%, hypothyroidism was 21% andeuthyroidism was observed 44%.KEYWORDS: Interferon, HCV, HBV, Thyroid Profile, Hepatocellular carcinoma, Immune Effect, cirrhosis